Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA483603
Max Phase: Preclinical
Molecular Formula: C21H20N4O
Molecular Weight: 344.42
Molecule Type: Small molecule
Associated Items:
ID: ALA483603
Max Phase: Preclinical
Molecular Formula: C21H20N4O
Molecular Weight: 344.42
Molecule Type: Small molecule
Associated Items:
Canonical SMILES: CCCNc1c2c(=O)nc(-c3ccccc3)nc-2n(C)c2ccccc12
Standard InChI: InChI=1S/C21H20N4O/c1-3-13-22-18-15-11-7-8-12-16(15)25(2)20-17(18)21(26)24-19(23-20)14-9-5-4-6-10-14/h4-12,22H,3,13H2,1-2H3
Standard InChI Key: SOJVUOGSWGFAHD-UHFFFAOYSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 344.42 | Molecular Weight (Monoisotopic): 344.1637 | AlogP: 3.92 | #Rotatable Bonds: 4 |
Polar Surface Area: 59.81 | Molecular Species: NEUTRAL | HBA: 5 | HBD: 1 |
#RO5 Violations: 0 | HBA (Lipinski): 5 | HBD (Lipinski): 1 | #RO5 Violations (Lipinski): 0 |
CX Acidic pKa: | CX Basic pKa: | CX LogP: 2.37 | CX LogD: 2.37 |
Aromatic Rings: 2 | Heavy Atoms: 26 | QED Weighted: 0.57 | Np Likeness Score: -0.84 |
1. Shrestha AR, Ali HI, Ashida N, Nagamatsu T.. (2008) Antitumor studies. Part 5: Synthesis, antitumor activity, and molecular docking study of 5-(monosubstituted amino)-2-deoxo-2-phenyl-5-deazaflavins., 16 (20): [PMID:18819815] [10.1016/j.bmc.2008.09.022] |
Source(1):